scholarly journals Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines

Circulation ◽  
2015 ◽  
Vol 132 (10) ◽  
pp. 916-922 ◽  
Author(s):  
Joseph Yeboah ◽  
Tamar S. Polonsky ◽  
Rebekah Young ◽  
Robyn L. McClelland ◽  
Joseph C. Delaney ◽  
...  
Keyword(s):  
Statin Therapy ◽  
American Heart Association ◽  
American Heart ◽  
Heart Association ◽  
Risk Markers ◽  
Cholesterol Guidelines

scholarly journals Impact of the American College of Cardiology/American Heart Association Cholesterol Guidelines on Statin Eligibility Among Human Immunodeficiency Virus-Infected Individuals

2018 ◽  
Vol 5 (12) ◽  
Author(s):  
Mosepele Mosepele ◽  
Susan Regan ◽  
Joseph Massaro ◽  
James B Meigs ◽  
Markella V Zanni ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Statin Therapy ◽  
American Heart Association ◽  
American Heart ◽  
Clinical Care ◽  
Heart Association ◽  
Cvd Risk ◽  
Immunodeficiency Virus ◽  
Statin Prescription ◽  
Cholesterol Guidelines

Abstract Background Individuals with human immunodeficiency virus (HIV) face elevated cardiovascular disease (CVD) risk. There are limited data regarding the application of the American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines in HIV compared with non-HIV patients. Methods Human immunodeficiency virus-infected and demographically similar control patients were assessed for statin recommendation status by ACC/AHA and the National Cholesterol Education Program Adult Treatment Program III (ATPIII), indication for statin recommendation, actual statin prescription, and CVD event. Outcomes were atherosclerotic CVD for ACC/AHA and coronary heart disease for ATPIII. Results In a clinical care cohort of 1394 patients infected with HIV, 38.6% (538 of 1394) of patients were recommended for statin therapy by the ACC/AHA guidelines compared with 20.1% (280 of 1394) by the ATPIII guidelines. Of those recommended for statin therapy, actual statin prescription rates were 42.8% (230 of 538) for ACC/AHA and 66.4% (186 of 280) for ATPIII. Among patients infected with HIV with an incident CVD event during follow-up, statin therapy was recommended for 59.2% (42 of 71) of patients by ACC/AHA and 35.2% (25 of 71) by ATPIII, versus 71.6% (141 of 197) by ACC/AHA and 43.1% (85 of 197) by ATPIII in the control group. Conclusions In an HIV clinical care cohort, the ACC/AHA cholesterol guidelines recommend a higher proportion of patients for statin therapy and identify an increased proportion of patients with a CVD event compared with ATPIII. However, 40% of patients with a CVD event would not have been recommended for statin therapy by ACC/AHA, compared with 29% for controls. This gap in identification of patients infected with HIV at high CVD risk underscores the need for HIV-specific cardiovascular prevention strategies.

scholarly journals The changing paradigm of dyslipidaemia management

2017 ◽  
Vol 36 (1) ◽  
pp. 1
Author(s):  
Ruvan Ekanayaka
Keyword(s):  
Cardiovascular Risk ◽  
Lipid Profile ◽  
Statin Therapy ◽  
American Heart Association ◽  
American Heart ◽  
Heart Association ◽  
Blood Cholesterol ◽  
Clinical Risk ◽  
Risk Criteria

<p>The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults,(1) effected a change in the paradigm of dyslipidaemia management, in that it no longer advocated a target based therapy but instead posited a primary clinical basis for initiation of statin therapy. The intensity of statin therapy too was guided by clinical risk criteria rather than by absolute values of the lipid profile.</p>

Sign in / Sign up

Export Citation Format

Share Document